{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:21:57Z","timestamp":1793305317180,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.xphs.2026.104190","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T17:10:00Z","timestamp":1770311400000},"page":"104190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advantages and limitations of the inclusion of ascorbic acid on nitrosamine mitigation in pharmaceutical drug products"],"prefix":"10.1016","volume":"115","author":[{"given":"Armen","family":"Mekhdjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Sarmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Najafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5166-1986","authenticated-orcid":false,"given":"Anh-Vu","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grassli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5090-5913","authenticated-orcid":false,"given":"Robert","family":"Araiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Pyrz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.xphs.2026.104190_bib0001","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1021\/acs.oprd.3c00100","article-title":"The nitrosamine \u201cSaga\u201d: lessons learned from five years of scrutiny","volume":"27","author":"Nudelman","year":"2023","journal-title":"Org Process Res Dev"},{"issue":"5","key":"10.1016\/j.xphs.2026.104190_bib0002","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.xphs.2023.02.014","article-title":"Solid state kinetics of nitrosation using native sources of nitrite","volume":"112","author":"Carloni","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104190_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2021.104926","article-title":"Use of Less-than-Lifetime (LTL) durational limits for nitrosamines: case study of N-nitrosodiethylamine (NDEA)","volume":"123","author":"Bercu","year":"2021","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.xphs.2026.104190_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105245","article-title":"Genotoxicity evaluation of a valsartan-related complex N-nitroso-impurity","volume":"134","author":"Glowienke","year":"2022","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.xphs.2026.104190_bib0005","series-title":"Guideline on Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk","year":"2026"},{"key":"10.1016\/j.xphs.2026.104190_bib0006","series-title":"FDA Statement on FDA\u2019s Ongoing Investigation Into Valsartan Impurities and Recalls and an Update On FDA\u2019s Current Findings","author":"Gottlieb","year":"2026"},{"issue":"9","key":"10.1016\/j.xphs.2026.104190_bib0007","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1016\/j.xphs.2021.04.021","article-title":"Nitrosamine contamination in pharmaceuticals: threat, impact, and control","volume":"110","author":"Tuesuwan","year":"2021","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104190_bib0008","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1208\/s12249-023-02523-w","article-title":"Nitroso impurities in drug products: an overview of risk assessment, regulatory milieu, and control strategy","volume":"24","author":"Charoo","year":"2023","journal-title":"AAPS PharmSciTech"},{"issue":"10","key":"10.1016\/j.xphs.2026.104190_bib0009","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/acs.oprd.3c00153","article-title":"Formation of N -nitrosamine drug substance related impurities in medicines: a regulatory perspective on risk factors and mitigation strategies","volume":"27","author":"Cioc","year":"2023","journal-title":"Org Process Res Dev"},{"issue":"5","key":"10.1016\/j.xphs.2026.104190_bib0010","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.xphs.2023.01.027","article-title":"N-Nitrosamine formation in pharmaceutical solid drug products: experimental observations","volume":"112","author":"Moser","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104190_bib0011","series-title":"A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products","year":"2026"},{"issue":"11","key":"10.1016\/j.xphs.2026.104190_bib0012","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1021\/acs.oprd.3c00274","article-title":"N -Nitrosodimethylamine formation in metformin drug products by the reaction of dimethylamine and atmospheric NO2","volume":"27","author":"Fukuda","year":"2023","journal-title":"Org Process Res Dev"},{"issue":"9","key":"10.1016\/j.xphs.2026.104190_bib0013","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1021\/acs.oprd.0c00323","article-title":"Pathways for N -nitroso compound formation: secondary amines and beyond","volume":"24","author":"L\u00f3pez-Rodr\u00edguez","year":"2020","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.xphs.2026.104190_bib0014","unstructured":"Neeta Joshi, R.J. Strategies For Mitigating N-Nitrosamine Impurities in Drug Products: A Comprehensive Review. 2024. 10.5281\/ZENODO.11228530."},{"issue":"7","key":"10.1016\/j.xphs.2026.104190_bib0015","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.xphs.2023.03.022","article-title":"N-Nitrosamine mitigation with nitrite scavengers in oral pharmaceutical drug products","volume":"112","author":"Bayne","year":"2023","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2026.104190_bib0016","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.3390\/pr10112428","article-title":"Assessment of a diverse array of nitrite scavengers in solution and solid state: a study of inhibitory effect on the formation of alkyl-aryl and dialkyl N-nitrosamine derivatives","volume":"10","author":"Hom\u0161ak","year":"2022","journal-title":"Processes"},{"issue":"12","key":"10.1016\/j.xphs.2026.104190_bib0017","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1016\/j.xphs.2021.08.010","article-title":"Inhibition of N-nitrosamine formation in drug products: a model study","volume":"110","author":"Nanda","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104190_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115066","article-title":"N-Nitrosodimethylamine formation in metformin hydrochloride sustained-release tablets: effects of metformin and hypromellose used in drug product formulation","volume":"222","author":"Hao","year":"2023","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2026.104190_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124832","article-title":"Nitrosamine mitigation: NDMA impurity formation and its inhibition in metformin hydrochloride tablets","volume":"666","author":"Shakleya","year":"2024","journal-title":"Int J Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2026.104190_bib0020","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1016\/j.xphs.2023.06.013","article-title":"Bumetanide as a model NDSRI substrate: N-nitrosobumetanide impurity formation and its inhibition in bumetanide tablets","volume":"112","author":"Shakleya","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104190_bib0021","series-title":"Control of Nitrosamine Impurities in Human Drugs","year":"2026"},{"issue":"10","key":"10.1016\/j.xphs.2026.104190_bib0022","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/BF00963487","article-title":"Mechanism of nitrosation of ascorbic acid by nitrite in neutral aqueous media","volume":"40","author":"Myshkin","year":"1991","journal-title":"Bull Acad Sci USSR Div Chem Sci"},{"key":"10.1016\/j.xphs.2026.104190_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.arres.2023.100079","article-title":"Ascorbate mediates the non-enzymatic reduction of nitrite to nitric oxide","volume":"9","author":"Du","year":"2023","journal-title":"Adv Redox Res"},{"issue":"6","key":"10.1016\/j.xphs.2026.104190_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e16498","article-title":"A concise summary of powder processing methodologies for flow enhancement","volume":"9","author":"Shah","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.xphs.2026.104190_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119571","article-title":"Development of low dose micro-tablets by high shear wet granulation process","volume":"587","author":"Gupta","year":"2020","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2026.104190_bib0026","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1081\/DDC-120030419","article-title":"Comparison of low shear, high shear, and fluid bed granulation during low dose tablet process development","volume":"30","author":"Hausman","year":"2004","journal-title":"Drug Dev Ind Pharm"},{"issue":"9","key":"10.1016\/j.xphs.2026.104190_bib0027","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1021\/acs.oprd.0c00224","article-title":"Potential for the formation of N-nitrosamines during the manufacture of active pharmaceutical ingredients: an assessment of the risk posed by trace nitrite in water","volume":"24","author":"Ashworth","year":"2020","journal-title":"Org Process Res Dev"},{"issue":"4043","key":"10.1016\/j.xphs.2026.104190_bib0028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1126\/science.177.4043.65","article-title":"Ascorbate-nitrite reaction: possible means of blocking the formation of carcinogenic N -nitroso compounds","volume":"177","author":"Mirvish","year":"1972","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.xphs.2026.104190_bib0029","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1021\/jf000147+","article-title":"Potential nitrite scavengers as inhibitors of the formation of N -nitrosamines in solution and tobacco matrix systems","volume":"48","author":"Rundl\u00f6f","year":"2000","journal-title":"J Agric Food Chem"},{"issue":"3","key":"10.1016\/j.xphs.2026.104190_bib0030","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s10973-011-2151-z","article-title":"Influence of temperature and humidity on the degradation process of ascorbic acid in vitamin C chewable tablets","volume":"111","author":"Pavlovska","year":"2013","journal-title":"J Therm Anal Calorim"},{"key":"10.1016\/j.xphs.2026.104190_bib0031","series-title":"Excipients in the Dossier for Application for Marketing Authorisation of a Medicinal Product - Scientific Guideline | European Medicines Agency (EMA)","year":"2026"},{"key":"10.1016\/j.xphs.2026.104190_bib0032","series-title":"Topic Q 8 (R2) Pharmaceutical Development","year":"2009"},{"key":"10.1016\/j.xphs.2026.104190_bib0033","series-title":"Impurities in New Drug Products","year":"2006"},{"issue":"3","key":"10.1016\/j.xphs.2026.104190_bib0034","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0039-9140(98)00280-X","article-title":"Moisture induced solid phase degradation of l-ascorbic acid","volume":"48","author":"Shephard","year":"1999","journal-title":"Talanta"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926000390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926000390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:34:34Z","timestamp":1774488874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926000390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0022354926000390"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104190","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advantages and limitations of the inclusion of ascorbic acid on nitrosamine mitigation in pharmaceutical drug products","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104190"}}